Genentech, Chiron Settle Herceptin Patent Dispute
The deal was disclosed Tuesday by Genentech in a regulatory filing to the U.S. Securities and Exchange Commission.
Genentech and Chiron settled their dispute in June, ending both interference proceedings at the U.S. Patent & Trademark Office and a lawsuit that had been appealed to the U.S. Court of Appeals for the Federal Circuit.
“Under the settlement agreement, Chiron has...
To view the full article, register now.